TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01297010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone and ondasetron
Description: Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
Study: NCT03341065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exoskeleton type robot

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: end-effector type robot
Study: NCT02976753

Intervention type: DRUG
Intervention: efmoroctocog alfa
Description: extended half-life factor VIII product

Intervention type: DRUG
Intervention: Factor VIII
Description: conventional factor VIII product
Study: NCT03362190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura in combination with Lucentis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura in combination with Lucentis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura in combination with Lucentis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura in combination with Lucentis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Zimura in combination with Lucentis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Zimura in combination with Lucentis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Zimura in combination with Lucentis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Zimura in combination with Lucentis
Study: NCT03559049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m\^2 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 600mg PO, BID days 1-21 of each 21 day cycle
Study: NCT04635995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVGN7409
Description: IV infusion once every 3 weeks (Q3W).
Study: NCT00476268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone/formoterol (100/6µg) pMDI
Description: Two puffs b.i.d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone dipropionate 250 µg/unit dose pMDI
Description: 2 inhalations bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol powder 12 µg/unit dose
Description: 2 inhalations bid
Study: NCT04462315

Intervention type: DRUG
Intervention: Everolimus Eluting Coronary Stent System
Description: Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation

Intervention type: DEVICE
Intervention: Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)
Description: Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
Study: NCT01055223

Intervention type: DRUG
Intervention: TZD only (RSG or PIO or troglitazone)
Description: Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.

Intervention type: DRUG
Intervention: TZD + spironolactone
Description: Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days.

Intervention type: DRUG
Intervention: TZD + amiloride
Description: Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days.
Study: NCT00950157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of information on approval based on a surrogate outcome and levels of caution
Description: Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of information on approval based on a surrogate outcome and levels of caution
Description: Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of information on approval based on a surrogate outcome and levels of caution
Description: Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement.
Study: NCT05898451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)
Description: has a direct antitumor effect in vitro and in vivo on various tumor cell lines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy
Description: Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
Study: NCT00796510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan = 100 mg tablet administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan and Sildenafil
Description: Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
Study: NCT02359604

Intervention type: DRUG
Group type: OTHER
Intervention: PPI therapy
Description: PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool sample
Description: Stool sample will be obtained before initiation of PPI (before PPI therapy)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool sample
Description: Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool sample
Description: Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
Study: NCT00622908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-403
Description: 0.6% TID, 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of ISV-403 TID, 5 days
Study: NCT04084756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Crisis Response Plan
Description: The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health Education
Description: The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
Study: NCT00544765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC
Description: Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC
Description: Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC
Description: Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX
Description: Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
Study: NCT03559387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANF-RHO™
Description: Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta®
Description: Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe.
Study: NCT02452645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Food and Physical Activity Environments
Description: Tailored written materials, videos, telephone counseling, active toys

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Group
Description: Written materials, videos, books, and telephone counseling.
Study: NCT05236777

Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.
Study: NCT02161237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf®
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf®
Description: oral
Study: NCT02726711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan will be infused (0.5 - 4.0 mg IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 - 4.0 mg IV to be infused
Study: NCT03798470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Addiction Counseling
Description: After identification, a 24/7 on-call FRC was paged and met with the patient in the ED. The patients were offered recovery services at the bedside by the FRC. The research team members offered voluntary participation and obtained informed consent to enrolling a longitudinal study looking into the success of his intervention. Patients did not need to participate to be eligible for counseling and resources from AVOR. The FRCs counselled and engaged the patient along with the family to offer a variety of services including active recovery coaching, group treatment modalities, family support services and transportation. After he initial encounter in the ED, the FAVOR team re-engaged the participant by phone or in person the next day and gradually increasing intervals thereafter.
Study: NCT05170841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg
Description: Administered as one single tablet to be taken every 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg
Description: Administered as one single tablet to be taken every 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol Hydrochloride 100 mg
Description: Administered as two capsules with 50 mg each to be taken every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride 100 mg
Description: Administered as two capsules with 50 mg each to be taken every 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg
Study: NCT03903094

Intervention type: OTHER
Intervention: Non-Interventional
Description: Overview of anticholinergic burden, rather than to evaluate specific drugs

Intervention type: OTHER
Intervention: Non-Interventional
Description: Overview of anticholinergic burden, rather than to evaluate specific drugs
Study: NCT03947580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the Dvectis Single pad
Description: Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Single pads compared to without using a pad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the Dvectis Double pad
Description: Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Double pad compared to without using a pad,~* Categorisation of adverse events,~* Categorisation of deficiencies of a medical device in patients enrolled in treatment groups using Dvectis Single and Dvectis Double pad,~* Number of patients with adverse events,~* Number of patients with deficiencies of medical device enrolled in treatment groups using Dvectis Single and Dvectis Double
Study: NCT03740347

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Response to questionnaires evaluating chronic pain and its repercussion :~* anxiety questionnaire (Revised Children's Manifest Anxiety Scale),~* depression questionnaire (Children's Depression Inventory score),~* sleepiness questionnaire (Pediatric Daytime Sleepiness Scale),~* quality of life questionnaire (Pediatric Quality of Life inventory score).
Study: NCT02740868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon-129 and Perfluoropropane (19F)
Description: Xenon gas and perfluoropropane to be inhaled by research participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon-129 and Perfluoropropane (19F)
Description: Xenon gas and perfluoropropane to be inhaled by research participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon-129 and Perfluoropropane (19F)
Description: Xenon gas and perfluoropropane to be inhaled by research participants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Lung imaging will be performed for participants using MRI for all 3 arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Lung imaging will be performed for participants using MRI for all 3 arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Lung imaging will be performed for participants using MRI for all 3 arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Clearance Index
Description: Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Clearance Index
Description: Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Clearance Index
Description: Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
Study: NCT03947580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of no pad
Description: Description is not needed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of no pad
Description: Description is not needed
Study: NCT00538343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berubicin hydrochloride (RTA 744)
Study: NCT02928848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
Study: NCT00886483

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Neurofeedback
Description: A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
Study: NCT03076177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping application
Description: Kinesio taping application will be applied for experimental group; non specific taping application for control

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Taping application
Description: Kinesio taping application will be applied for experimental group; non specific taping application for control
Study: NCT00182091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human growth hormone
Description: Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To maintain study-subject blinding, doses were sham adjusted.
Study: NCT03246295

Intervention type: OTHER
Intervention: lifestyle intervention or insulin treatment
Description: Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
Study: NCT02971046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: varying protein intakes
Description: In healthy school-aged children: Four randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are 0.95, 1.3,1.55, and 2.0 grams per kilogram of bodyweight per day.~In healthy young and old adults: Up to six randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are : 0.66, 0.8, 1, 1.2, and 1.5 grams per kilogram of bodyweight per day.
Study: NCT02914795

Intervention type: OTHER
Intervention: diagnostic analysis of platelet function
Description: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique

Intervention type: OTHER
Intervention: diagnostic analysis of platelet function
Description: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
Study: NCT03648437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 10Mg/mL
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 10Mg/mL
Description: Experimental drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.45% Sodium Chloride
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.45% Sodium Chloride
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Standard therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Standard therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: Standard therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Standard therapy
Study: NCT04448522

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: reduced dosage IMRT
Description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：63.6Gy/30Fr/2.12Gy; PTVnd：63.6Gy/30Fr/2.12Gy; PTV1：54Gy/30Fr/1.8Gy; PTV2：49.2Gy/30Fr/1.64Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional dosage IMRT
Description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：69.96Gy/33Fr/2.12Gy; PTVnd：69.96Gy/33Fr/2.12Gy; PTV1：59.4Gy/33Fr/1.8Gy; PTV2：54Gy/33Fr/1.64Gy
Study: NCT05131126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet method
Description: This operation consists of fixing a bone graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different arms exercices
Description: Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~* Perform 5 circumduction movements with the right and left arms~* Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different arms exercices
Description: Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~* Perform 5 circumduction movements with the right and left arms~* Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation.
Study: NCT04081480

Intervention type: DRUG
Group type: OTHER
Intervention: Valacyclovir
Description: PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution